Literature DB >> 26911190

Leukaemia 'firsts' in cancer research and treatment.

Mel Greaves1.   

Abstract

Our understanding of cancer biology has been radically transformed over recent years with a more realistic grasp of its multilayered cellular and genetic complexity. These advances are being translated into more selective and effective treatment of cancers and, although there are still considerable challenges, particularly with drug resistance and metastatic disease, many patients with otherwise lethal malignancies now enjoy protracted remissions or cure. One largely unheralded theme of this story is the extent to which new biological insights and novel clinical applications have their origins with leukaemia and related blood cell cancers, including lymphoma. In this Timeline article, I review the remarkable and ground-breaking role that studies in leukaemia have had at the forefront of this progress.

Entities:  

Mesh:

Year:  2016        PMID: 26911190     DOI: 10.1038/nrc.2016.3

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  174 in total

Review 1.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 2.  Differentiation-linked leukemogenesis in lymphocytes.

Authors:  M F Greaves
Journal:  Science       Date:  1986-11-07       Impact factor: 47.728

3.  ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

Authors:  D Bhojwani; D Pei; J T Sandlund; S Jeha; R C Ribeiro; J E Rubnitz; S C Raimondi; S Shurtleff; M Onciu; C Cheng; E Coustan-Smith; W P Bowman; S C Howard; M L Metzger; H Inaba; W Leung; W E Evans; D Campana; M V Relling; C-H Pui
Journal:  Leukemia       Date:  2011-08-26       Impact factor: 11.528

Review 4.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

5.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

Authors:  Peter Eirew; Adi Steif; Jaswinder Khattra; Gavin Ha; Damian Yap; Hossein Farahani; Karen Gelmon; Stephen Chia; Colin Mar; Adrian Wan; Emma Laks; Justina Biele; Karey Shumansky; Jamie Rosner; Andrew McPherson; Cydney Nielsen; Andrew J L Roth; Calvin Lefebvre; Ali Bashashati; Camila de Souza; Celia Siu; Radhouane Aniba; Jazmine Brimhall; Arusha Oloumi; Tomo Osako; Alejandra Bruna; Jose L Sandoval; Teresa Algara; Wendy Greenwood; Kaston Leung; Hongwei Cheng; Hui Xue; Yuzhuo Wang; Dong Lin; Andrew J Mungall; Richard Moore; Yongjun Zhao; Julie Lorette; Long Nguyen; David Huntsman; Connie J Eaves; Carl Hansen; Marco A Marra; Carlos Caldas; Sohrab P Shah; Samuel Aparicio
Journal:  Nature       Date:  2014-11-26       Impact factor: 49.962

Review 6.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Authors:  Robert R Jenq; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

Review 7.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

Review 8.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

9.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

Review 10.  Cancer genomics: one cell at a time.

Authors:  Nicholas E Navin
Journal:  Genome Biol       Date:  2014-08-30       Impact factor: 13.583

View more
  22 in total

1.  The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.

Authors:  Lan Deng; Ling Jiang; Xiang-Hua Lin; Kuo-Fu Tseng; Yuan Liu; Xing Zhang; Rui-Hong Dong; Zhi-Gang Lu; Xiu-Ju Wang
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

2.  Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density.

Authors:  Sapan J Patel; Costel C Darie; Bayard D Clarkson
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

3.  Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells.

Authors:  Fang Dong; Haitao Bai; Xiaofang Wang; Shanshan Zhang; Zhao Wang; Miner Xie; Sen Zhang; Jinhong Wang; Sha Hao; Tao Cheng; Hideo Ema
Journal:  Blood Adv       Date:  2019-02-12

4.  Chlorambucil-Iron Oxide Nanoparticles as a Drug Delivery System for Leukemia Cancer Cells.

Authors:  Samer Hasan Hussein-Al-Ali; Mohd Zobir Hussein; Saifullah Bullo; Palanisamy Arulselvan
Journal:  Int J Nanomedicine       Date:  2021-09-08

5.  Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity.

Authors:  Alberto M Parra-Perez; Amalia Pérez-Jiménez; Isabel Gris-Cárdenas; Gloria C Bonel-Pérez; Luis M Carrasco-Díaz; Khalida Mokhtari; Leticia García-Salguero; José A Lupiáñez; Eva E Rufino-Palomares
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

6.  Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009.

Authors:  Chris Bailey; Lisa C Richardson; Claudia Allemani; Audrey Bonaventure; Rhea Harewood; Angela R Moore; Sherri L Stewart; Hannah K Weir; Michel P Coleman
Journal:  Cancer       Date:  2018-10-21       Impact factor: 6.860

Review 7.  Clonal evolution in leukemia.

Authors:  Adolfo A Ferrando; Carlos López-Otín
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

Review 8.  Molecular pathology of cancer: how to communicate with disease.

Authors:  Peter Birner; Gerald Prager; Berthold Streubel
Journal:  ESMO Open       Date:  2016-11-17

Review 9.  Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia.

Authors:  Silvia Basilico; Berthold Göttgens
Journal:  J Mol Med (Berl)       Date:  2017-04-20       Impact factor: 4.599

10.  c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation.

Authors:  Guixian Wu; Ting Liu; Han Li; Yafang Li; Dengju Li; Wenhua Li
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.